# HORMONE THERAPIES & GLYCEMIC CONTROL



Executive Insights into Endocrine Optimization and Metabolic Outcomes

MARK L. GORDON, M.D.

# The Influence of Hormone Replacement Therapies on Hypoglycemia and Hyperglycemia: A Neuroendocrine Perspective

Mark L. Gordon, MD

## Introduction

Hormone replacement therapies (HRT), often prescribed for conditions such as menopause, andropause, adrenal insufficiency, or post-traumatic neuroendocrine dysfunction, exert profound systemic and central nervous system effects. Beyond their primary target tissues, these hormones—particularly sex steroids, corticosteroids, thyroid hormones, and neurosteroids—significantly modulate glucose metabolism. Alterations in glucose homeostasis, resulting in either hypoglycemia or hyperglycemia, can be a direct consequence of these interventions. Understanding the complex crosstalk between exogenous hormones and the hypothalamic-pituitary axis, pancreatic islets, adipose tissue, liver, and brain is critical for optimizing therapeutic outcomes and minimizing metabolic risks.

## Mechanisms by Which HRT Influences Glucose Homeostasis

### Sex Steroids: Estrogen, Progesterone, and Testosterone

Estrogen replacement, especially in its bioidentical form (17β-estradiol), enhances insulin sensitivity by improving GLUT4 translocation, reducing hepatic gluconeogenesis, and modulating inflammatory cytokines such as IL-6 and TNF-α. However, synthetic estrogens can impair hepatic insulin extraction and raise triglyceride levels, thereby contributing to hyperglycemia in some users. Progesterone, particularly in high or unopposed doses, reduces insulin sensitivity and can exacerbate fasting glucose levels, partly through its antagonistic effect on estrogen and interference with insulin receptor signaling.

Testosterone replacement in hypogonadal males generally improves insulin sensitivity, enhances lean body mass, and reduces visceral adiposity. These metabolic improvements can reduce hyperglycemia and HbA1c levels. However, supraphysiologic testosterone dosing may induce erythrocytosis, vascular resistance, and in rare cases, exacerbate insulin resistance via increased aromatization to estradiol and dysregulation of adiponectin.

### Corticosteroids and Adrenal Neurosteroids

Glucocorticoids, whether endogenous or exogenously administered (e.g., hydrocortisone, dexamethasone), are potent inducers of hyperglycemia. They increase hepatic gluconeogenesis, inhibit insulin secretion, and impair glucose uptake in muscle and adipose tissue. Chronic corticosteroid therapy is a leading cause of iatrogenic diabetes mellitus. Furthermore, cortisol modulates glucose-sensing neurons in the hypothalamus, blunting counter-regulatory responses and potentially worsening hypoglycemia.

Adrenal neurosteroids such as dehydroepiandrosterone (DHEA) and its sulfated form (DHEA-S) play a role in modulating insulin signaling through peroxisome proliferator-activated receptor gamma (PPAR-γ) and AMP-activated protein kinase (AMPK) pathways. Replacement of DHEA in deficient individuals has been associated with improved insulin sensitivity, reduced inflammatory markers, and decreased central obesity, particularly in women with adrenal insufficiency or aging-related decline.

### Thyroid Hormones and Glucose Regulation

Thyroid hormones accelerate basal metabolic rate and enhance hepatic glucose output. Hyperthyroidism (or excessive replacement) leads to increased gluconeogenesis, glycogenolysis, and intestinal glucose absorption, thereby promoting hyperglycemia. Conversely, hypothyroidism, or under-replacement, is linked to impaired insulin secretion and reduced glucose disposal, potentially increasing the risk for postprandial hypoglycemia.

### Neurosteroids and Neuroactive Steroids

Neurosteroids such as allopregnanolone, pregnanolone, and tetrahydrodeoxycorticosterone (THDOC) modulate GABA_A receptors and influence both mood and autonomic regulation. These compounds indirectly affect glycemic control by modulating the hypothalamic-pituitary-adrenal (HPA) axis, autonomic tone, and neuroinflammatory status.

Allopregnanolone, derived from progesterone, has been shown to increase parasympathetic tone and promote insulin secretion. It may contribute to reactive hypoglycemia in susceptible individuals, especially in those receiving high-dose progesterone-based HRT or during luteal phases of the menstrual cycle. On the other hand, chronic stress reduces allopregnanolone levels, increases cortisol, and shifts metabolism toward hyperglycemia.

Pregnenolone, the precursor of all neurosteroids, supports hippocampal function and HPA feedback. Its supplementation may reduce HPA axis overactivation, indirectly curbing cortisol-mediated hyperglycemia. However, unbalanced neurosteroid replacement without appropriate monitoring can result in glycemic variability, particularly when underlying stress, inflammation, or neurodegeneration are present.

### Neuroactive Steroids and Central Glucose Sensing

Many neurosteroids cross the blood-brain barrier and interact with central glucose-sensing neurons in the arcuate nucleus, nucleus of the solitary tract, and ventromedial hypothalamus. Modulation of these circuits impacts insulin secretion, glucagon response, and sympathetic nervous system activity. The dysregulation of this neurocircuitry—either by excessive or deficient hormone replacement—may contribute to blunted awareness of hypoglycemia (e.g., in cortisol or growth hormone deficiency) or chronic hyperglycemia (e.g., in excess glucocorticoid states).

### Clinical Implications

Patients receiving HRT—whether for adrenal, gonadal, thyroid, or neuroendocrine insufficiencies—must be regularly monitored for fasting glucose, HbA1c, and postprandial glycemic excursions. Those with traumatic brain injury, PTSD, chronic stress, or age-related hormonal decline are particularly vulnerable to glucose dysregulation due to underlying hypothalamic and pituitary disruption. Integration of biomarker-guided therapy, can help tailor treatment and reduce the risk of adverse glycemic outcomes.

### Chart: Influence of Key Hormones in HRT on Glucose Metabolism

| **Hormone / Steroid** | **Glycemic Effect** | **Mechanism** | **Risk for Hypo-/Hyperglycemia** |
|---|---|---|---|
| Estradiol | ↑ Insulin sensitivity | ↑ GLUT4, ↓ inflammation | May cause **hypoglycemia** |
| Progesterone | ↓ Insulin sensitivity | Antagonizes estrogen, modulates insulin receptor | Mild hyperglycemia |
| Testosterone | ↑ Insulin sensitivity | ↑ Lean mass, ↓ fat mass, ↑ GLUT4 expression | May cause **hypoglycemia** |
| DHEA / DHEA-S | ↓ Inflammation, ↑ sensitivity | Activates PPAR-γ, ↓ cytokines | Stabilizing, variable |
| Cortisol / Prednisone | ↑ Gluconeogenesis | ↓ Insulin secretion, ↑ hepatic output | Hyperglycemia |
| Allopregnanolone | ↑ Insulin secretion | Enhances GABAergic tone, parasympathetic activity | Risk of reactive **hypoglycemia** |
| Pregnenolone | ↓ HPA hyperactivity | Modulates cortisol production and neuroinflammation | Stabilizing |
| T3 / T4 | ↑ Metabolic rate | ↑ Glucose absorption, ↑ hepatic output | Hyperglycemia (overdose) |

## Symptoms of Hyperglycemia and Hypoglycemia: A Neuroendocrine Context

Recognizing the clinical manifestations of glycemic imbalance is vital when evaluating patients undergoing hormone replacement therapy (HRT). Both hyperglycemia and hypoglycemia may emerge as consequences of exogenous hormonal manipulation, but hypoglycemia presents a more immediate and potentially lifethreatening neurophysiological risk, particularly in individuals with neuroendocrine dysfunction or impaired counter-regulatory hormone responses.

Hyperglycemia, most frequently observed in the context of excessive glucocorticoid administration or thyroid hormone overdose, often develops gradually. Patients may exhibit increased urination and thirst due to osmotic diuresis, along with generalized fatigue, diminished energy, and blurred vision. The immunosuppressive effects of hyperglycemia increase susceptibility to infections, while cognitive fog and headaches are not uncommon. In more advanced cases, unintended weight loss may occur, especially in catabolic states such as uncontrolled diabetes, and wound healing may become notably delayed. Though these symptoms may be subtle in onset, persistent hyperglycemia contributes to endothelial dysfunction, neuropathy, and neuroinflammation, thereby exacerbating cognitive decline, mood instability, and autonomic imbalance—particularly in those already struggling with hormonal dysregulation.

Hypoglycemia, in contrast, has a more acute presentation and can be particularly dangerous in individuals with diminished hypothalamic or adrenal function, such as patients recovering from traumatic brain injury or those with adrenal insufficiency. It involves both autonomic and neuroglycopenic symptom clusters. Autonomic manifestations include sensations of palpitations, tremors, diaphoresis, and nausea, often accompanied by a sense of anxiety or panic and an intense urge to eat. These symptoms arise from the catecholamine surge triggered by declining glucose levels. As blood glucose drops further, neuroglycopenic symptoms emerge due to reduced cerebral glucose availability. Patients may experience confusion, blurred vision, slurred or slowed speech, irritability, and abrupt mood changes. In more severe instances, seizures, loss of consciousness, or even coma may occur.

Notably, patients receiving neurosteroid-based therapies—such as those involving allopregnanolone, progesterone, or pregnenolone—may have diminished awareness of hypoglycemia. This blunting effect is attributed to enhanced GABAergic tone, which can dampen the responsiveness of hypothalamic glucose-sensing neurons. Progesterone in particular has been linked to parasympathetic predominance and increased vagal activity, which may further obscure the sympathetic cues typically associated with early-stage hypoglycemia. Consequently, warning signs may be delayed or absent until a more dangerous threshold is reached.

The risk is further magnified in patients with a history of adrenal suppression—whether from chronic corticosteroid use or from post-traumatic hypothalamic-pituitary-adrenal (HPA) axis disruption—due to an impaired cortisol response to falling blood glucose. These patients may fail to mount an adequate counter-regulatory defense, rendering them more susceptible to severe hypoglycemia. Initiating therapies such as thyroid hormones or testosterone, both of which increase cellular glucose uptake, can precipitate a rapid decline in blood glucose if adrenal capacity is not concurrently supported.

Importantly, the symptoms of hypoglycemia can mimic those seen in neuropsychiatric disorders. Panic attacks, dissociative episodes, and acute depressive states may, in some cases, reflect underlying metabolic instability rather than purely psychological origins. For this reason, it is critical to assess glucose levels in patients presenting with abrupt mood or cognitive shifts, particularly those undergoing HRT or those with known neuroendocrine vulnerabilities.

**Nocturnal Hypoglycemia: A Silent Disruptor of Neuroendocrine Stability**

Nocturnal hypoglycemia is a frequently overlooked yet clinically significant phenomenon, particularly in individuals undergoing hormone replacement therapy or those with impaired hypothalamic-pituitary-adrenal (HPA) axis function. Occurring during sleep, this form of hypoglycemia can be asymptomatic or present with subtle autonomic signs that are often misattributed to unrelated sleep disturbances. It represents a critical disruption in glycemic control, with downstream effects on both endocrine regulation and central nervous system function.

During the night, endogenous insulin sensitivity tends to increase due to circadian variations in cortisol and growth hormone secretion. In healthy individuals, the nocturnal rise in cortisol and pulsatile release of growth hormone provide a counter-regulatory buffer that maintains euglycemia despite prolonged fasting. However, patients on exogenous hormone replacement—especially those with blunted adrenal or pituitary reserve—may lack this compensatory mechanism. In such cases, nighttime hypoglycemia can develop, often unrecognized, and can exacerbate systemic and neurological vulnerability.

The physiological consequences of nocturnal hypoglycemia extend beyond mere glucose deprivation. Recurrent low blood sugar during sleep triggers surges in epinephrine, norepinephrine, and cortisol in a delayed attempt to restore glycemia. These surges can result in fragmented sleep, nightmares, profuse sweating, and tachycardia. Upon awakening, individuals may report morning headaches, fatigue, irritability, or feelings of unrested sleep—symptoms that are commonly mistaken for psychiatric or primary sleep disorders.

Moreover, nocturnal hypoglycemia has been implicated in impaired cognitive performance, mood instability, and neuroinflammation due to insufficient overnight glucose delivery to the brain. This is particularly relevant in patients with neurodegenerative conditions or those using neurosteroids such as progesterone, allopregnanolone, or pregnenolone, which can modulate GABAergic tone and suppress autonomic alerting systems. As a result, patients may sleep through hypoglycemic episodes without overt awakening or adrenergic symptoms, even as neuronal glucose deprivation silently undermines cerebral function.

In individuals with testosterone or thyroid hormone replacement, the increase in metabolic rate and glucose uptake—especially in the context of insufficient dietary intake before bedtime or disrupted cortisol rhythms—can further precipitate nocturnal hypoglycemia. This risk is compounded in those with relative adrenal insufficiency or a history of traumatic brain injury affecting hypothalamic-pituitary regulation.

Clinically, nocturnal hypoglycemia should be suspected in patients who experience unexplained insomnia, morning fatigue, cold sweats upon waking, or significant mood lability. Confirmatory testing may involve continuous glucose monitoring or early-morning fasting glucose measurements. Preventive strategies include ensuring a balanced bedtime snack with complex carbohydrates and protein, adjusting HRT timing or dosing, and optimizing adrenal support with physiologic cortisol replacement when necessary.

## Conclusion

Hormone replacement therapies are indispensable tools for restoring physiological integrity across endocrine, neurological, and metabolic domains. However, their intricate influence on glucose regulation demands careful consideration, particularly in individuals with neuroendocrine compromise, chronic stress, or traumatic brain injury. Sex steroids, thyroid hormones, corticosteroids, and neurosteroids exert multifaceted effects on glucose homeostasis by altering central hypothalamic signaling, modulating peripheral insulin sensitivity, and shaping systemic inflammatory tone. These effects, while often therapeutic, can also precipitate hypoglycemia or hyperglycemia if not precisely balanced.

Among the most insidious complications is nocturnal hypoglycemia—a silent disruptor of neuroendocrine stability that may elude standard diagnostic scrutiny. Occurring during the vulnerable sleep cycle, it undermines brain function, triggers maladaptive hormonal surges, and degrades sleep quality and cognitive resilience. This hidden metabolic instability can be further exacerbated by neurosteroid-induced suppression of autonomic responses or insufficient adrenal compensation. Consequently, optimal outcomes in HRT require more than just biochemical replacement; they demand a personalized, biomarker-guided strategy that anticipates and addresses the dynamic interplay between hormones and glucose metabolism over the 24-hour cycle. Vigilant monitoring and timely therapeutic adjustments not only preserve metabolic balance but also safeguard neurological function, enhance quality of life, and restore the delicate equilibrium of the neuroendocrine axis.